With BPC-157
Complementary evidenceLv2
An exploratory rat Achilles-tendon study found improved histology versus control for the combination, but no additional benefit over either peptide alone.
Interaction evidence sourceFDA TB-500 assessment All research profiles
Blends
GLOW
Prepared by the ezGLP team. Sources last checked . Profile reviewed .
Also known as GHK-Cu + BPC-157 + TB-500
Routes represented in the knowledgebase: Subcutaneous (SubQ).
Educational overview
GLOW is listed in the ezGLP knowledgebase under Blends. Evidence and regulatory status can vary by formulation, route, and jurisdiction.
GLOW is a vendor name for a fixed-ratio compounded blend marketed for skin and tissue repair, most often built around GHK-Cu with BPC-157 and TB-500. It is a trade label rather than a defined formulation, and composition varies by seller: some vials are sold under the name with a different third peptide or a different ratio, so the name alone does not identify the contents. GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, studied mainly in cell culture and in topical cosmetic work. BPC-157 is a synthetic 15-amino-acid peptide, and TB-500 a short synthetic fragment of thymosin beta-4.
Fixed-ratio compounded blends have no combined trial evidence, and no published study has tested these peptides administered together. Evidence for the parts does not transfer to the mixture, and the parts are supported mostly by preclinical work. Human GHK-Cu data are confined to small, often industry-funded topical cosmetic studies of skin firmness and wrinkles, with no controlled trial of the injected form; a 2025 systematic review in orthopaedic sports medicine found no high-quality human evidence for BPC-157; and no human clinical trial of TB-500 has been published. Findings from topical GHK-Cu creams in particular say nothing about injected exposure inside a blend.
Regulators treat these products as unapproved compounded preparations. GHK-Cu is legal and widely sold as a cosmetic ingredient, but no injectable form is approved anywhere, and in 2023 the FDA placed injectable GHK-Cu, BPC-157, and thymosin beta-4 with its TB-500 fragment on its list of bulk drug substances that may present significant safety risks when compounded, citing immunogenicity, aggregation, peptide-related impurities, and limited human data. In sport, BPC-157 is named on the WADA Prohibited List under S0 and thymosin beta-4 and its derivatives under S2, both prohibited at all times; GHK-Cu is not named, although S0 covers non-approved substances generally.
The blend is supplied as a lyophilized powder in a single vial, usually blue-tinted from the copper complex, and reconstituted before subcutaneous injection. Fading of that colour can indicate copper loss or degradation, but no approved label sets a storage temperature or beyond-use time and no stability data cover three peptides and a copper complex sharing one solution. Because the ratio is fixed by the seller and cannot be reconstructed after reconstitution, an inventory record for GLOW generally names each component and its stated amount per vial alongside lot number, reconstitution date, resulting concentration, injection site, and any local reaction.
- Category
- Blends
- Routes represented
- Subcutaneous (SubQ)
- Storage context
- Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.
Published literature
Safety evidence
Serious or important: potential immunogenicity, aggregation, impurity, or product-quality risks.
A dependable route-specific human interaction and side-effect profile is not established; this is not evidence of no risk.
Safety evidence sourceInteraction evidence
These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
With BPC-157
Complementary evidenceLv1
The pair is proposed as complementary from separate preclinical findings involving tendon repair, angiogenic signaling, collagen, and extracellular-matrix accumulation.
Interaction evidence sourceGHK-Cu wound studyFDA peptide safety overviewWith GHK-Cu
Complementary evidenceLv1
The pair is proposed as complementary from separate evidence involving thymosin-beta-4-related cell migration and GHK-Cu-associated matrix accumulation.
Interaction evidence sourceGHK-Cu wound studyFDA TB-500 assessmentWith KPV
Complementary evidenceLv1
The pair is proposed as complementary through separate preclinical rationales involving tissue migration, remodeling, and inflammatory signaling.
Interaction evidence sourceKPV preclinical studyFDA KPV assessmentWith KPV
Complementary evidenceLv1
The pair is proposed as complementary from separate preclinical findings involving extracellular-matrix deposition and reduced inflammatory signaling.
Interaction evidence sourceKPV preclinical studyFDA KPV assessmentCommon questions
What is in the GLOW peptide blend?
Most vials sold under the name contain GHK-Cu together with BPC-157 and TB-500, and the catalogue entry here records that trio. There is no standard recipe: the ratio between components differs between sellers, some substitute or add a peptide, and no regulator has reviewed any version. The certificate of analysis for a specific batch is the only description of what that vial holds.
Is GLOW peptide FDA approved?
No. None of its components is an approved injectable medicine, and no regulator has reviewed the combination. In 2023 the FDA placed injectable GHK-Cu, BPC-157, and thymosin beta-4 with its TB-500 fragment among bulk drug substances that may present significant safety risks when compounded, which removes them from routine compounding under section 503A. GHK-Cu remains legal as a topical cosmetic ingredient, a separate regulatory category.
What is the difference between GLOW and KLOW?
KLOW is the same family of blend with KPV added, the tripeptide lysine-proline-valine from the C-terminal end of alpha-melanocyte-stimulating hormone, which is marketed for an anti-inflammatory rationale drawn from mouse colitis studies. GLOW is generally sold without it. Both names are vendor conventions, both vary in ratio between sellers, and neither combination has been tested in any published study.
Does injected GHK-Cu do what the skincare studies show?
That has not been established. Human GHK-Cu evidence comes from small topical studies of creams and serums measuring skin firmness, wrinkle depth, and photodamage, several of them industry-funded. No controlled human trial of injected GHK-Cu has been published, and the FDA's 2023 assessment for the injectable route noted limited human data. Exposure from a cosmetic cream and from an injected blend are not comparable.
Further reading
- Pickart et al., International Journal of Molecular Sciences 2018 (GHK-Cu gene data review)
- Pickart and Margolina, 2015 (GHK in skin regeneration, review)
- Vasireddi et al., HSS Journal 2025 (systematic review, orthopaedic sports medicine)
- Biological activities of thymosin beta-4 defined by active peptide sequences, FASEB Journal 2010
- FDA, thymosin beta-4 fragment (TB-500) compounding safety assessment
- FDA, bulk drug substances that may present significant safety risks (2023)
- WADA Prohibited List (S0 non-approved substances; S2 peptide hormones and growth factors)
Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live. Consult a licensed healthcare professional.